HRP20181583T1 - Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata - Google Patents

Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata

Info

Publication number
HRP20181583T1
HRP20181583T1 HRP20181583TT HRP20181583T HRP20181583T1 HR P20181583 T1 HRP20181583 T1 HR P20181583T1 HR P20181583T T HRP20181583T T HR P20181583TT HR P20181583 T HRP20181583 T HR P20181583T HR P20181583 T1 HRP20181583 T1 HR P20181583T1
Authority
HR
Croatia
Prior art keywords
carbamoyl
ethenylcyclopropylcarboxylic
iloxy
cyclopropylsulfonyl
dimethylpropyl
Prior art date
Application number
HRP20181583TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181583(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland filed Critical Bristol-Myers Squibb Holdings Ireland
Publication of HRP20181583T1 publication Critical patent/HRP20181583T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20181583TT 2012-05-07 2013-04-30 Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata HRP20181583T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
EP13722217.0A EP2846780B1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
HRP20181583T1 true HRP20181583T1 (hr) 2018-11-30

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181583TT HRP20181583T1 (hr) 2012-05-07 2013-04-30 Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata

Country Status (33)

Country Link
US (1) US20130302414A1 (https=)
EP (1) EP2846780B1 (https=)
JP (1) JP6276756B2 (https=)
KR (1) KR20150004921A (https=)
CN (1) CN104363899A (https=)
AR (1) AR090954A1 (https=)
AU (1) AU2013260005B2 (https=)
BR (1) BR112014027676A2 (https=)
CA (1) CA2872765A1 (https=)
CL (1) CL2014003012A1 (https=)
CO (1) CO7141457A2 (https=)
CY (1) CY1120756T1 (https=)
DK (1) DK2846780T3 (https=)
EA (1) EA028749B1 (https=)
ES (1) ES2688817T3 (https=)
HR (1) HRP20181583T1 (https=)
IL (1) IL235466B (https=)
LT (1) LT2846780T (https=)
MX (1) MX358545B (https=)
MY (1) MY171378A (https=)
NZ (1) NZ630248A (https=)
PE (1) PE20142439A1 (https=)
PH (1) PH12014502405A1 (https=)
PL (1) PL2846780T3 (https=)
PT (1) PT2846780T (https=)
RS (1) RS57881B1 (https=)
SG (1) SG11201406964QA (https=)
SI (1) SI2846780T1 (https=)
SM (1) SMT201800506T1 (https=)
TW (1) TWI577392B (https=)
UY (1) UY34785A (https=)
WO (1) WO2013169520A1 (https=)
ZA (1) ZA201408967B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846778B1 (en) * 2012-05-07 2018-04-25 Bristol-Myers Squibb Holdings Ireland Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
JP7433252B2 (ja) 2018-03-14 2024-02-19 キャンディ・セラピューティクス・リミテッド Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤
US11464764B2 (en) * 2018-12-19 2022-10-11 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
NZ526169A (en) * 2000-10-31 2005-12-23 Boehringer Ingelheim Pharma Oral dosage self-emulsifying formulations of pyranone protease inhibitors
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
IL235466B (en) 2019-03-31
CY1120756T1 (el) 2019-12-11
SG11201406964QA (en) 2014-11-27
ES2688817T3 (es) 2018-11-07
KR20150004921A (ko) 2015-01-13
TWI577392B (zh) 2017-04-11
PE20142439A1 (es) 2015-01-28
LT2846780T (lt) 2018-11-12
CN104363899A (zh) 2015-02-18
UY34785A (es) 2013-11-29
RS57881B1 (sr) 2019-01-31
JP2015516418A (ja) 2015-06-11
AR090954A1 (es) 2014-12-17
EP2846780B1 (en) 2018-07-18
BR112014027676A2 (pt) 2017-06-27
PL2846780T3 (pl) 2018-11-30
MX358545B (es) 2018-08-24
AU2013260005B2 (en) 2017-07-13
HK1204552A1 (en) 2015-11-27
CA2872765A1 (en) 2013-11-14
PT2846780T (pt) 2018-10-26
DK2846780T3 (en) 2018-09-17
ZA201408967B (en) 2016-10-26
EA201492039A1 (ru) 2015-02-27
WO2013169520A1 (en) 2013-11-14
EA028749B1 (ru) 2017-12-29
NZ630248A (en) 2016-11-25
CO7141457A2 (es) 2014-12-12
SMT201800506T1 (it) 2018-11-09
TW201350145A (zh) 2013-12-16
SI2846780T1 (sl) 2018-09-28
JP6276756B2 (ja) 2018-02-07
CL2014003012A1 (es) 2015-07-10
AU2013260005A1 (en) 2015-01-15
EP2846780A1 (en) 2015-03-18
MY171378A (en) 2019-10-10
PH12014502405A1 (en) 2015-01-12
MX2014013220A (es) 2015-05-11
US20130302414A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
HRP20181583T1 (hr) Formulacija solubilizirane kapsule 1,1-dimetiletil[(1s)-1-{[(2s,4r)-4-(7-kloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
BR112012030906A2 (pt) derivados de carbamato de hexaflúor isopropila, sua preparação e sua aplicação terapêutica
WO2014052360A3 (en) Glycoprotein preparations
WO2013126746A3 (en) Dll3 modulators and methods of use
EP3024472A4 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
IL232333A (en) N- (pyrid-4-ram) amides and n- (pyrimidin-4-ram) amides and their pharmacological and cosmetic uses
HUS2300030I1 (hu) N-(2-metoxibenzoil)-4-[(metilaminokarbonil)amino]benzolszulfonamid polimorf formája
PL2964023T3 (pl) Zastosowanie n-(2-metoksybenzoilo)- 4-[(metyloaminokarbonylo)amino]benzenosulfonamidu w kombinacji ze środkiem owadobójczym lub fungicydem dla zwiększenia plonów roślin
PT2849745T (pt) Composição farmacêutica compreendendo (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano[3,4,b]indol]-4-amina e ibuprofeno
BR112014028574A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um gabapentinoide
BR112014028562A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e antidepressivos
BR112014028569A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um oxicam
EP2882435B8 (en) Pharmaceutical formulations containing 3-(4-cinnamyl-L-piperazinyl) amino derivatives of 3-formylrifamycin S
BR112014028566A2 (pt) composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar.
TH1401006625A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
EP2890368A4 (en) RECIPE FOR A DOUBLE-LAYER COMPOSITE TABLET WITH ATORVASTATIN, IRBESARTAN AND MAGNESIUM CARBONATE
ZA201403735B (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
EA201401272A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и парацетамол или пропацетамол
BR112014028564A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um componente de ácido salicílico
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo
ZA201602238B (en) Preservative free pharmaceutical composition for ophthalmic administration containing bimatoprost and timolol
HK1224596A1 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
TH156288A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต